Objective To explore the anticancer and T cellular immune effects of Sheganfuzheng oral liquid (SOL) on experimental H22 Hepatoma-bearing mice. Methods The mice bearing H22 hepatocellular carcinoma were established and randomly divided into four groups: tumor control group, low-dose (9.64 g raw materials/kg) SOL group, high-dose (19.28 g raw materials/kg) SOL group, and 5-fluorouracil group. 14 days later, the transplanted tumor, thymus and spleen were excised from the treatment mice and weighted to calculate the tumor growth inhibitory rate, thymus index and spleen index respectively. T lymphocyte subsets in peripheral blood of treatment mice were assessed by flowcytometry. Results The tumor inhibitory rates of SOL high and low dose group were 14.2% and 9.4%. The thymus index (4.67±0.50 mg/g) and spleen index (3.42±0.49 mg/g) in the high-dose SOL group were markedly higher (P <0.05) than those in the tumor control group. The percentage of CD3+ T cells, CD4+ T cells and CD8+ T cells, the ratio 1.80±0.26 of CD4+/CD8+ T cells in the high-dose SOL group were significantly higher (P <0.05) than those in the tumor control group. Conclusion SOL can obviously inhibit the growth of transplanted tumor, improve immune imbalance state of T cell subsets and increase the T lymphocyte function on experimental H22 hepatoma-bearing mice.%目的 探讨射干扶正口服液对H22肝癌荷瘤小鼠的抑瘤作用及T细胞功能的影响.方法 建立H22小鼠实体瘤模型,随机分为模型对照组、射干扶正口服液高剂量组(19.28 g生药/kg)、射干扶正口服液低剂量组(9.64 g生药/kg)、5-氟尿嘧啶组(0.15 g/kg)共4组.连续给药14 d后,比较各组瘤重并计算抑瘤率、胸腺指数、脾脏指数；流式细胞仪检测各组小鼠外周血T细胞亚群的变化.结果 射干扶正口服液高、低剂量组抑瘤率分别为14.2％、9.4％.与模型对照组相比,射干扶正口服液高剂量组小鼠脾脏指数(4.67士0.50 mg/g)及胸腺指数(3.42±0.49 mg/g)明显升高(P＜0.05),外周血中CD3+T细胞、CD4+T细胞和CD8+T细胞比例均回升(P＜0.05),CD4+/CD8+T细胞比值升高为1.80±0.26 (P＜0.05).结论 射干扶正口服液能抑制小鼠H22实体瘤的生长,并改善CD4+T细胞与CD8+T细胞亚群的失衡状态,提高肝癌小鼠的T细胞免疫功能.
展开▼
